Intellectual Property
Our patented technology for carbohydrate attachment is wholly owned by Design-Zyme LLC. We are actively pursuing intellectual property protection of our discoveries and products. The company has multiple allowed US patents and is aggressively seeking patent protection from the USPTO and PCT for our broad range of discoveries. Design-Zyme maintains in-house patent counsel to oversee maintenance and prosecution of its patent estate.
Issued Patents
In Vitro Glycosylation of Proteins and Enzymes - The present invention comprises a glycosylated protein wherein the starting protein has an amino sidechain with a nucleophilic moiety which reacts with a carbohydrate having an oxazoline moiety on the reducing end to covalently bond the amino sidechain of the starting protein with the oxazoline moiety. The glycosylated protein substantially retains the structure and function of the starting protein.
In Vitro Glycosylation of Proteins and Enzymes - The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least ∼7500 Da. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.
In Vitro Glycosylation of Proteins and Enzymes - The present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety. The glycosylated protein substantially retains the structure and function of the starting protein. This is the parent application for the in vitro glycosylation platform.
Published Patent Applications - Pending
U.S. Pat. Appl. 18/196,214
Universal Adjuvant for Nasal, Oral, and Intramuscular Delivery of Vaccines - The present invention is broadly concerned with a vaccine composition comprising at least one immunogen modified by in vitro glycosylation methods. In particular, this method generates glycosylated versions of immunogens via the reducing end of a linear carbohydrate with a reducing end containing an N-acyl-2-amino moiety. This invention allows for the custom control of placement and amounts of a linear carbohydrate on the immunogen. The immunogen may be singular or attached to a nanoparticle. The glycosylated immunogen of the vaccine composition may be self-adjuvanting for enteral, parenteral, topical, intravaginal, and intranasal delivery.
PCT Appl. No. PCT/US23/
23550
Universal Adjuvant for Nasal, Oral, and Intramuscular Delivery of Vaccines - The present invention is broadly concerned with a vaccine composition comprising at least one immunogen modified by in vitro glycosylation methods. In particular, this method generates glycosylated versions of immunogens via the reducing end of a linear carbohydrate with a reducing end containing an N-acyl-2-amino moiety. This invention allows for the custom control of placement and amounts of a linear carbohydrate on the immunogen. The immunogen may be singular or attached to a nanoparticle. The glycosylated immunogen of the vaccine composition may be self-adjuvanting for enteral, parenteral, topical, intravaginal, and intranasal delivery.
U.S. Pat. Appl. 18/499,765
Self-Adjuvanting Multi-Protein Complexes for Modular Vaccine Production - The present invention is broadly concerned with a vaccine composition comprising a central carrier, at least one linear carbohydrate molecule, and at least one immunogen molecule, wherein each of the at least one linear carbohydrate molecule and at least one immunogen molecule are covalently bound to the carrier via respective covalent linkages. Vaccine compositions comprising multivalent carriers and related methods may find various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection, including, but are not limited to, coronaviruses, Lyme Disease, Chlamydia, and the related diseases thereof.
PCT Appl. No. PCT/US23/
78438
Self-Adjuvanting Multi-Protein Complexes for Modular Vaccine Production - The present invention is broadly concerned with a vaccine composition comprising a central carrier, at least one linear carbohydrate molecule, and at least one immunogen molecule, wherein each of the at least one linear carbohydrate molecule and at least one immunogen molecule are covalently bound to the carrier via respective covalent linkages. Vaccine compositions comprising multivalent carriers and related methods may find various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection, including, but are not limited to, coronaviruses, Lyme Disease, Chlamydia, and the related diseases thereof.
U.S. Pat. Appl. 19/256,289
A Vaccine Composition for Lyme Disease - The present invention is broadly concerned with a vaccine compositions comprising a plurality of immunogens attached to a carrier for inducing an immune response against a pathogen selected from the Anaplasma, Babesia, Borrelia, and Chlamydia genera. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing an infection caused by the Anaplasma, Babesia, Borrelia, or Chlamydia pathogens, and the related diseases thereof.
Patent Applications Pending
USPTO No. 63/839,174
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,178
A novel xylazine hapten for vaccines against xylazine exposure
USPTO No. 63/839,180
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,182
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,184
A novel nitazene hapten for vaccine development against fentanyl opioids
USPTO No. 63/839,189
A novel poly-hapten vaccine for opioid use disorder